Blue Shield of California's Bold Move to Bypass PBMs and Decrease Humira Costs
Wednesday, 2 October 2024, 04:06
Blue Shield's Innovation in Pricing
Starting January 1, 2025, Blue Shield of California will offer its commercial members a remarkable opportunity by bypassing PBMs, leading to a dramatic 90% reduction in Humira pricing. Most members will utilize Fresenius Kabi's adalimumab-aacf, a Humira biosimilar, with $0 out-of-pocket expenses. This strategic decision aims to alleviate financial burdens on patients and promote better accessibility to critical medications.
Impact on Patients and Healthcare System
- This public health initiative enhances access to essential treatments.
- It reflects ongoing efforts to curtail drug costs and provide equitable healthcare solutions.
- By improving affordability, Blue Shield of California encourages adherence to necessary treatments.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.